BackBiomarin Pharmaceutical - Registered Shares Overview
Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical - Registered Shares Target Price

See Biomarin Pharmaceutical - Registered Shares's analyst price targets ($94) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$57.54

Average Target Price

$93.9463.3% upside

16 analysts in the last 4 months

High: $124 | Low: $59

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-15BMO Capital$9768.6% upsideOpen
2026-09-01Cantor Fitzgerald$8649.5% upsideOpen
2026-09-01Piper Sandler$9056.4% upsideOpen
2026-08-31JefferiesAkash Tewari$10582.5% upsideOpen
2026-08-31Raymond James$10989.4% upsideOpen
2026-08-26UBS$8852.9% upsideOpen
2026-08-18BMO CapitalDavid Lebowitz$9870.3% upsideOpen
2026-08-18H.C. Wainwright$592.5% upsideOpen
2026-08-17Piper Sandler$8852.9% upsideOpen
2026-08-17BarclaysEliana Merle$11192.9% upsideOpen
2026-08-10Canaccord GenuityWhitney Ijem$11498.1% upsideOpen
2026-08-07Raymond James$10582.5% upsideOpen
2026-08-07Morgan Stanley$124115.5% upsideOpen
2026-08-07Stifel Nicolaus$7021.7% upsideOpen
2026-08-07OppenheimerLeland Gershell$9768.6% upsideOpen
2026-07-07RBC CapitalLuca Issi$627.8% upsideOpen
2026-05-22Canaccord Genuity$11192.9% upsideOpen
2026-05-18Leerink Partners$627.8% upsideOpen
2026-05-18H.C. Wainwright$5013.1% downsideOpen
2026-05-11Goldman Sachs$6919.9% upsideOpen
2026-05-05Evercore ISI$120108.6% upsideOpen
2026-05-05Tudor PickeringWilliam Pickering$8242.5% upsideOpen
2026-04-27Morgan StanleySean Laaman$120108.6% upsideOpen
2026-03-12JefferiesAkash Tewari$10379% upsideOpen
2026-03-03BarclaysEliana Merle$10582.5% upsideOpen
2026-03-02Loop Capital MarketsIlya Zubkov$10582.5% upsideOpen
2026-02-26Canaccord GenuityWhitney Ijem$10480.7% upsideOpen
2026-02-24Oppenheimer$9565.1% upsideOpen
2026-02-24Stifel NicolausPaul Matteis$6818.2% upsideOpen
2026-02-18Wells Fargo$7530.3% upsideOpen
2026-02-06Piper Sandler$8446% upsideOpen
2026-01-20Canaccord Genuity$9870.3% upsideOpen
2025-12-23Truist FinancialJoon Lee$10073.8% upsideOpen
2025-12-22H.C. Wainwright$604.3% upsideOpen
2025-12-03Leerink Partners$604.3% upsideOpen
2025-11-03Tudor PickeringWilliam Pickering$8852.9% upsideOpen
2025-11-03Bernstein$8852.9% upsideOpen
2025-10-28RBC CapitalLuca Issi$6614.7% upsideOpen
2025-10-28Stifel Nicolaus$7326.9% upsideOpen
2025-10-28Truist FinancialJoon Lee$8039% upsideOpen
2025-10-28Morgan StanleySean Laaman$9870.3% upsideOpen
2025-10-28H.C. Wainwright$554.4% downsideOpen
2025-10-28Wells FargoMohit Bansal$7021.7% upsideOpen
2025-10-28Barclays$8039% upsideOpen
2025-08-05UBS$11498.1% upsideOpen
2025-07-15Wolfe ResearchAkash Tewari$9565.1% upsideOpen
2024-10-30Cantor FitzgeraldOlivia Brayer$9056.4% upsideOpen
2024-10-30Robert W. BairdJack Allen$6513% upsideOpen
2024-10-30CitigroupDavid Lebowitz$8140.8% upsideOpen
2024-10-10Raymond JamesDanielle Brill$7937.3% upsideOpen

Biomarin Pharmaceutical - Registered Shares (BMRN) FAQ

Biomarin Pharmaceutical - Registered Shares posts a target price of $94. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $94 for BMRN means covering analysts, on average, see the stock 63.3% upside of $57.54 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BMRN's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Biomarin Pharmaceutical - Registered Shares's other metric pages and overview cover the third.

Judging Biomarin Pharmaceutical - Registered Shares against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $94 here, then scan peer and history charts to see if the gap is persistent.